Scarica l'app Stockscreener
174.95
2.48%
4.23
Dopo l'orario di chiusura:
174.95
Precedente Chiudi:
$170.72
Aprire:
$172.95
Volume 24 ore:
1.30M
Relative Volume:
1.41
Capitalizzazione di mercato:
$8.61B
Reddito:
$4.06B
Utile/perdita netta:
$413.08M
Rapporto P/E:
21.84
EPS:
8.01
Flusso di cassa netto:
$560.48M
1 W Prestazione:
+1.63%
1M Prestazione:
+15.40%
6M Prestazione:
+67.82%
1 anno Prestazione:
-10.33%
Intervallo 1D:
$172.00
$177.75
Intervallo di 1 settimana:
$166.86
$177.75
Portata 52W:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Confronta CRL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
174.95 | 8.37B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
536.78 | 198.56B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
210.92 | 147.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
637.34 | 50.96B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
141.10 | 39.13B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
205.75 | 34.81B | 15.70B | 1.24B | 2.01B | 6.9036 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-05-08 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-03 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Downgrade | UBS | Buy → Neutral |
| 2024-11-18 | Downgrade | CLSA | Hold → Underperform |
| 2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
| 2024-10-23 | Iniziato | CLSA | Underperform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Sell |
| 2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
| 2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Downgrade | Argus | Buy → Hold |
| 2024-06-07 | Iniziato | Mizuho | Neutral |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Why Charles River Laboratories International Inc. stock is seen as undervalued2025 Bull vs Bear & Safe Capital Growth Tips - newser.com
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $205 From $185, Maintains Buy Rating - MarketScreener
Biologics Safety Testing Market to Rise at 13.64% CAGR, Soars USD 14.45 Bn by 2034 - GlobeNewswire Inc.
Charles River Labs forms Scientific Advisory Board to advance NAMs By Investing.com - Investing.com Nigeria
Charles River Labs taps former FDA leader to help move away from animal tests - The Business Journals
Key resistance and support levels for Charles River Laboratories International Inc.July 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoptio - PharmiWeb.com
Fairjourney Biologics acquires Charles River Laboratories South San Francisco facility - MSN
Charles River Labs forms Scientific Advisory Board to advance NAMs - Investing.com India
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption - Business Wire
Can you recover from losses in Charles River Laboratories International Inc.July 2025 Closing Moves & Fast Gain Stock Trading Tips - newser.com
What does recent volatility data suggest for Charles River Laboratories International Inc.Weekly Investment Recap & Verified Stock Trade Ideas - newser.com
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call - BioSpace
A Look at Charles River Laboratories' Valuation Following Strategic ReproTracker Partnership with Toxys - simplywall.st
How to integrate Charles River Laboratories International Inc. into portfolio analysis toolsJuly 2025 Final Week & Growth-Oriented Investment Plans - newser.com
Why hedge funds are buying Charles River Laboratories International Inc. stockJuly 2025 Analyst Calls & Long-Term Growth Stock Strategies - newser.com
Will Charles River Laboratories International Inc. (RV6) stock sustain uptrend momentumJuly 2025 Review & Technical Pattern Recognition Alerts - newser.com
Will Charles River Laboratories International Inc. bounce back from current supportQuarterly Profit Review & Target Return Focused Stock Picks - newser.com
Tick level data insight on Charles River Laboratories International Inc. volatilityEntry Point & Real-Time Buy Signal Alerts - newser.com
Understanding Charles River Laboratories International Inc.’s price movement2025 Technical Patterns & Risk Managed Investment Signals - newser.com
TD Cowen Adjusts Price Target on Charles River Laboratories International to $205 From $179, Maintains Buy Rating - MarketScreener
Charles River Laboratories (CRL): Investor Outlook Reveals Potential 8.68% Upside - DirectorsTalk Interviews
Allspring Global Investments Holdings LLC Acquires 516,521 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Sold by Truist Financial Corp - MarketBeat
Could Charles River (CRL) Redefine Its Competitive Edge with New Non-Animal Toxicology Platform? - simplywall.st
Charles River Laboratories International, Inc. $CRL Shares Sold by Lawson Kroeker Investment Management Inc. NE - MarketBeat
Janney Montgomery Scott LLC Has $1.58 Million Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs (CRL): Examining Valuation Following Recent Share Price Rebound - Yahoo Finance
Charles River Laboratories International Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Why Charles River Laboratories International Inc. (RV6) stock is trending on social mediaGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Published on: 2025-10-10 13:12:55 - newser.com
Can Charles River Laboratories International Inc. stock deliver strong Q4 earningsWeekly Risk Report & AI Powered Buy and Sell Recommendations - newser.com
Weiss Ratings Reiterates "Sell (D)" Rating for Charles River Laboratories International (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc. stock prediction for this weekCPI Data & Expert Approved Momentum Ideas - newser.com
Published on: 2025-10-09 06:30:08 - newser.com
Does Charles River Laboratories International Inc. (RV6) stock trade below intrinsic valueQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com
Is Charles River Laboratories International Inc. (RV6) stock positioned for digital growth eraInsider Buying & Stock Portfolio Risk Control - newser.com
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing - BioSpace
Winners And Losers Of Q2: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Drug Development Inputs & Services Stocks - Yahoo Finance
What drives Charles River Laboratories International Inc stock priceMorning Star Patterns & High Yield Portfolio Picks - earlytimes.in
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicit - PharmiWeb.com
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):